Abstracts tagged "Medicare"

Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Sang Hee Park¹, Taylor Schwartz², Xue Han¹, Scott Robinson², Sumie Kakehi¹, Keith Wittstock¹, Kris Norris², Anne Murunga², Alison Silverstein² and Jeffrey Sparks³, ¹Bristol Myers Squibb, Princeton, NJ, ²Avalere Health, Washington, DC, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
Abstract Number: 0464 • ACR Convergence 2021
The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
Maria Schletzbaum¹, Nadia Sweet², W Ryan Powell², Andrea Gilmore Bykovskyi³, Farah Kaiksow², Ann Sheehy², Amy Kind² and Christie Bartels², ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin - Madison School of Nursing, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) has the 6th highest hospital readmission rate of all US chronic diseases with significant health disparities and costs. Transitional care…
Abstract Number: 0587 • ACR Convergence 2021
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Akhil Sood¹, Yong-Fang Kuo², Jordan Westra² and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for opioid use. Disease-modifying antirheumatic drugs (DMARDs) have led to better control of disease activity.…
Abstract Number: 0611 • ACR Convergence 2021
Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists
Shannon Tai¹, Ikechukwu Mbonu² and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, West Allis, WI, ³Medical College of Wisconsin, Brookfield, WI
Background/Purpose: Geographic disparities in the distribution and practice patterns of rheumatology providers may negatively impact patients with rheumatic diseases. The objective of this study was…
Abstract Number: 0614 • ACR Convergence 2021
Sex and Race Based Utilization of Healthcare for Ocular Inflammation and Infection: Comparing the Results from the Medicare and the IRIS Data
Krati Chauhan¹ and James T. Rosenbaum², ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Health care utilization has an impact on disease progression and outcome in rheumatologic care. Disparities based on race, sex, education and income level affect…
Abstract Number: 0055 • ACR Convergence 2020
Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm
Krati Chauhan¹ and James Rosenbaum², ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Disparities in health care utilization based on sex, race, education, or income affect outcomes in rheumatologic care. We have used ocular inflammatory and infectious…
Abstract Number: 0181 • ACR Convergence 2020
Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
Yunjung Choi¹, Chang-Hun Lee¹, Myeung-Su Lee², Chang-Hoon Lee², SoJeong Park³ and Wan-Hee Yoo⁴, ¹Jeonbuk National University Hospital, Jeonju, Republic of Korea, ²Wonkwang University Hospital, Iksan, Republic of Korea, ³Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, ⁴Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea
Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
Abstract Number: 0533 • ACR Convergence 2020
Characterization of Older Male Patients with a Fragility Fracture
Setareh A Williams¹, Shanette G Daigle², Richard Weiss¹, Yamei Wang¹, Tarun Arora² and Jeffrey R Curtis³, ¹Radius Health, Inc., Waltham, MA, Waltham, MA, ²University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoporosis is associated with significant burden in terms of adverse patient outcomes, mortality, and cost; and is particularly common in the older Medicare population.…
Abstract Number: 0609 • ACR Convergence 2020
Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)
Shuang Song¹, Jeffrey Katz² and Elena Losina², ¹Brigham and Women's Hospital, Brighton, MA, ²Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA
Background/Purpose: Depressive symptoms are prevalent among knee OA (KOA) patients and likely lead to additional medical costs. We sought to quantify the prevalence of depressive…
Abstract Number: 0612 • ACR Convergence 2020
Differences in 30-Day Rehospitalization Risk and Predictors by Age Group Among Patients with Lupus in Medicare
Maria Schletzbaum¹, Yi Chen², Ann Sheehy³, Farah Kaiksow³, Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Hospital Medicine Division, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division, Madison, WI, ⁵University of Wisconsin - Madison, School of Nursing, Madison, WI, ⁶University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Although our recent research demonstrates that young adult Medicare beneficiaries (age 18-35) with lupus (SLE) have higher risk of 30-day rehospitalization, predictors specific to…
Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Christie Bartels¹, Maria Schletzbaum², Yi Chen³ and Amy Kind⁴, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, ⁴University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…
Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Zachary Wallace¹, Xiaoqing Fu², John Stone³, Hyon Choi⁴ and Rochelle Walensky², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…
Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
James Harnett¹, Timothy Smith ¹, John Woolcott ², David Gruben ³ and Christopher Murray ², ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
Abstract Number: 2333 • 2019 ACR/ARP Annual Meeting
Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Iris Navarro-Millan¹, Mangala Rajan ¹, Geyanne Lui ¹, Lisa Kern ¹, Laura Pinheiro ¹, Sebastian E. Sattui ², Lisa Mandl ³, Fenglong Xie ⁴, Jeffrey Curtis ⁵ and Monika Safford ¹, ¹Weill Cornell Medicine, New York, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with RA have high risk for myocardial infarction (MI). A meta-analysis showed that the age and sex adjusted pooled relative risk of MI…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].